Assessment of vaccine coverage following the introduction of a publicly funded pneumococcal vaccine program for the elderly in Victoria, Australia

被引:32
作者
Andrews, RM
机构
[1] Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT, Australia
[2] Univ Melbourne, Royal Childrens Hosp, Murdoch Childrens Res Inst, Dept Pediat,Clin Epidemiol & Biostat Unit, Parkville, Vic 3052, Australia
[3] Univ Melbourne, Royal Childrens Hosp, Murdoch Childrens Res Inst, Ctr Int Child Hlth, Parkville, Vic 3052, Australia
关键词
pneumococcal polysaccharide vaccine coverage; elderly; validity;
D O I
10.1016/j.vaccine.2004.11.039
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In 1998, a publicly funded pneumococcal vaccine program was introduced for persons aged >= 65 years in Victoria, Australia. In 2000, vaccine coverage over the previous 5 years was assessed through a telephone survey of 385 randomly selected subjects aged >= 65 years. Self-reported pneumococcal vaccine coverage within the previous 5 years was 46.0% (95% CI 40.5-51.6). Self-report was validated against the medical records of the nominated provider for 278 (72%) subjects. Among this subgroup, self-reported coverage was 51.1% but was 57.9% according to medical records (positive predictive value 91.5%, negative predictive value 77.2%, sensitivity 80.7%, specificity 89.7%). After accounting for response bias among those subjects for whom self-report was not validated, the revised estimate of pneumococcal vaccine coverage within the previous 5 years was 50.5% (95% CI 44.8-56.1). Comparison of vaccine coverage over time suggests the introduction of the publicly funded program in Victoria has dramatically increased coverage among the elderly. (c) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2756 / 2761
页数:6
相关论文
共 19 条
[1]   Cost-effectiveness of pneumococcal vaccination of older people:: A study in 5 western European countries [J].
Ament, A ;
Baltussen, R ;
Duru, G ;
Rigaud-Bully, C ;
de Graeve, D ;
Örtqvist, Å ;
Jönsson, B ;
Verhaegen, J ;
Gaillat, J ;
Christie, P ;
Cifre, AS ;
Vivas, D ;
Loiseau, C ;
Fedson, DS .
CLINICAL INFECTIOUS DISEASES, 2000, 31 (02) :444-450
[2]   Pneumococcal vaccination and pneumonia: Even a low level of clinical effectiveness is highly cost-effective [J].
Ament, A ;
Fedson, DS ;
Christie, P .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (12) :2078-2079
[3]  
Andrews RM, 2000, MED J AUSTRALIA, V173, pS45
[4]  
[Anonymous], NATL INFLUENZA SURVE
[5]  
*CDCP, 2001, EPI INF 6 WORD PROC
[6]  
Forrest J M, 2000, Commun Dis Intell, V24, P89
[7]  
*HLTH INS COMM, 2003, PHARM BEN SCHED IT S
[8]   The number needed to vaccinate (NNV) and population extensions of the NNV: comparison of influenza and pneumococcal vaccine programmes for people aged 65 years and over [J].
Kelly, H ;
Attia, J ;
Andrews, R ;
Heller, RF .
VACCINE, 2004, 22 (17-18) :2192-2198
[9]  
LONG CE, 1999, AM PUBL HLTH ASS ANN, P124
[10]   Validation of self-report of influenza and pneumococcal vaccination status in elderly outpatients [J].
Mac Donald, R ;
Baken, L ;
Nelson, A ;
Nichol, KL .
AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 1999, 16 (03) :173-177